Institut de Bioquímica Clínica, Servei de Bioquímica i Genètica Molecular, Hospital Clínic, Barcelona, Spain.
Clin Genet. 2010 May;77(5):474-82. doi: 10.1111/j.1399-0004.2009.01313.x. Epub 2009 Dec 10.
We screened for PDHA1 mutations in 40 patients with biochemically demonstrated PDHc deficiency or strong clinical suspicion, and found changes with probable pathological significance in 20. Five patients presented new mutations: p.A169V, c.932_938del, c.1143_1144 ins24, c.1146_1159dup and c.510-30G> A, this latter is a new undescribed cause of exon 6 skipping. Another four mutations have been found, and previously reported, in our patients: p.H113D, p.P172L, p.Y243del and p.Y369Q. Eleven patients presented seven known mutations: p.R127Q, p.I166I, p.A198T, p.R263G, p.R302C, p.R378C and c.1142_1145dup. The latter three were found in more than one unrelated patient: p.R302C was detected in a heterozygous girl and a mosaic male, p.R378C in two males and finally, c.1142_1145dup in three females; only one in 20 mothers was found to be a carrier (p.R263G). Apart from those 20 patients, the only alteration detected in one girl with clear PDHc and PDH-E1 deficiency was the silent change c.396A> C (p.R132R), and other eight PDHc deficient patients carry combinations of known infrequent polymorphisms that are overrepresented among our 20 unsolved patients. The importance of these changes on PDH activity is unclear. Investigations in the other PDHc genes are in course in order to elucidate the genetic defect in the unresolved patients.
我们对 40 名生化证实的 PDHC 缺陷或强烈临床怀疑的患者进行了 PDHA1 突变筛查,发现了 20 名具有可能病理意义的变化。5 名患者出现了新的突变:p.A169V、c.932_938del、c.1143_1144ins24、c.1146_1159dup 和 c.510-30G>A,后者是外显子 6 跳跃的新的未描述的原因。另外 4 个突变在我们的患者中已经发现并以前报道过:p.H113D、p.P172L、p.Y243del 和 p.Y369Q。11 名患者有 7 种已知的突变:p.R127Q、p.I166I、p.A198T、p.R263G、p.R302C、p.R378C 和 c.1142_1145dup。后三种在不止一位非相关患者中发现:p.R302C 被检测到在一个杂合女孩和一个镶嵌男孩中,p.R378C 在两个男孩中,最后 c.1142_1145dup 在三个女孩中;20 个母亲中只有一个被发现是携带者(p.R263G)。除了这 20 名患者外,另一名 PDHC 和 PDH-E1 缺陷明显的女孩仅发现了一个沉默的变化 c.396A>C(p.R132R),其他 8 名 PDHC 缺陷患者携带常见的罕见多态性组合,在我们 20 名未解决的患者中过度代表。这些变化对 PDH 活性的重要性尚不清楚。正在进行其他 PDHC 基因的研究,以便阐明未解决患者的遗传缺陷。